ELAN Q4 2024 Earnings — Elanco Animal Health Incorporated Revenue & Financial Results | Market Cap Arena

ELANElanco Animal Health Incorporated

$12B

Q4 2024 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$1.0B-1.4% YoY

Gross Profit

$389M38.1% margin

Operating Income

$8M0.8% margin

Net Income

-$8M-0.8% margin

EPS (Diluted)

$-0.02

QoQ Revenue Growth

-1.0%

Cash Flow

Operating Cash Flow

$177M

Free Cash Flow

$124M

Stock-Based Comp.

$15M

Balance Sheet

Total Assets

$12.6B

Total Liabilities

$6.5B

Stockholders' Equity

$6.1B

Cash & Equivalents

$468M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$1.0B	$1.0B	-1.4%
Gross Profit	$389M	$381M	+2.1%
Operating Income	$8M	$10M	-20.0%
Net Income	-$8M	-$141M	+94.3%

Revenue Segments

Farm Animal

$1.2B35%

Pet Health

$1.0B31%

Cattle

$510M15%

Poultry

$411M12%

Swine

$194M6%

Contract Manufacturing

$22M1%

Geographic Segments

Non-US

$545M53%

UNITED STATES

$475M47%